What happened
UK-based Basecamp Research, supported by Nvidia and Microsoft, introduced an AI-driven capability for gene therapies. This system leverages a species genomic sequence database to develop treatments for cancers and superbugs, thereby integrating advanced AI processing with extensive biological data for therapeutic discovery.
Why it matters
The introduction of this AI-driven gene therapy development, supported by major technology firms, creates new dependencies on external AI models and large genomic datasets for pharmaceutical research and development. This increases the oversight burden for regulatory compliance and data governance teams regarding the provenance, bias, and validation of AI outputs and the integrity of genomic data sources.
